Banner

What's New

Innovative resource for your improved understanding of
specialty diseases

Monthly Archives: January 2017

CAR-T cell: clinical awareness and importance – MDoutlook Insights

mdoutlook-total-oncology-intelligence-sq
How has the 58th ASH Annual Meeting been received by the oncology community? How much does attendance at this (or other major meetings) impact the uptake of the new clinical information? MDoutlook’s® innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 58th ASH Annual Meeting in San Diego will help you understand these questions, in addition to the specific clinical topics covered by our research.

Building on over 40 analyses covering ASH, ASCO, SABCS, ESMO and ESH for nearly a decade, this is our second report from the 2016 ASH meeting. We are proud to support the entire cancer community with this research.

This OncoPoll™ report focuses on the development of CAR-T Cell therapies for a variety of hematologic malignancies. It examines a number of target antigen + malignancy therapies in development plus some additional thoughts meaning on their impact in oncologist’s practice today – although none are yet commercially available.

Our analyses of the meeting impact on US oncologists (study sample n=100, see graphic) this year compares the different impact of the conference on those who attended the conference versus those who learned about the news from other sources as well treatment setting.MDoutlook CAR-T OncoPoll 2016 response

  • US oncologists are relatively aware of and see the development of CAR-T Cell therapies as very important to the B-lineage malignancies for which they are currently being studied. The leading CAR-T Cell approach, CD19-targeted in B-Cell acute lymphocytic leukemia, slightly leads the pack in both awareness and expected importance
  • Even though CAR-T Cell therapies are not yet commercially available, oncologists are up-to-date about them in their routine practices:
    • Referral of patients to the clinical trials is common, overall averaging about 4 per respondent over the past year
    • Oncologists, especially ASH attendees, frequently are being asked about these approaches by their patients, even outside of the clinical trial setting
  • The involvement of NIH in the development of CAR-T Cell therapies is seen as a positive for US oncologists
  • Attendance at the meeting is not necessary for this new information to impact clinical practices. While initial awareness of the information may be lower, upon learning about it, the physicians who did not attend recognize the clinical importance to a similar extent as those who did attend

Download your complimentary copy of our report MDoutlook OncoPoll report from ASH 2016 on CAR-T-Cell Therapies.

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review.

To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136.

December 2016 OncoPoll – B-Cell Lymphomas

mdoutlook-total-oncology-intelligence-sqMDoutlook® proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 58th ASH Annual Meeting in San Diego. Supporting the entire cancer community and building on over 40 analyses covering ASH since 2008, this is our first report from the 2016 meeting.

This OncoPoll™ focuses on B-cell lymphomas. It covers the choice between Rituxan® and Gazyva® in the front line setting for different lymphomas and the use of Rituxan and Revlimid® in the maintenance setting.

Our analyses of the meeting impact on US oncologists this year ((study sample n=100, see graphic) compares the different impact of the conference on those who attended the conference versus those who learned about the news from other sources:NHL-B-Cell OncoPoll ASH 2016 Respondents
• Oncologists see the comparison of the anti-CD20 antibodies Rituxan and Gazyva, in combination with chemotherapy in the front line setting for follicular and diffuse large B-cell lymphomas, as important clinical developments
• Overall usage of Gazyva in the front-line setting is expected to rise at the expense of Rituxan
• Use of maintenance strategies, with Rituxan in mantle cell lymphoma and Revlimid in CLL, is expected to continue to rise in popularity for hematologic malignancies
• Attendance at the meeting is not necessary for this new information to impact clinical practices. While initial awareness of the information may be lower, upon learning about it, the physicians who did not attend are just as, if not more likely to change their practices to integrate the clinical improvements

Download your complimentary copy of our report MDoutlook OncoPoll report from ASH 2016 on NHL-B-Cell.

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.

To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136.